Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Eligible age
65+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most efficacious dose of the senolytic fisetin to reduce the composite cardiovascular, respiratory, and renal sequential organ failure assessment score at 1 week, and predict the probability of success of a definitive phase III clinical trial.
Sponsor: University of Minnesota
You may qualify if…
- ✓ Age \>=65 years
- ✓ Primary diagnosis of acute infection (per investigator judgment)
- ✓ SOFA \>1
- ✓ Admission order to the hospital
- ✓ Expected length of stay \>=48 hours (per investigator judgment)
You may not qualify if…
- ✕ Admission to the ICU
- ✕ Vasopressors, mechanical ventilation, or dialysis
- ✕ Comfort care only
- ✕ Total bilirubin \>3X or AST/ALT \>4x upper limit of normal
- ✕ eGFR \< 25 ml/ min/ 1.73 m2
- ✕ Hemoglobin \<7 g/dL; white blood cell count ≤ 2,000/mm3; absolute neutrophil count ≤1 x 10\^9/;, or platelet count ≤ 40,000/μL
- ✕ Known HIV, Hepatitis B, or Hepatitis C
- ✕ Invasive fungal infection (per investigator judgment)
Where it's recruiting
Gainesville
Iowa City
Burnsville · Edina · Maplewood · Minneapolis
Jackson
Source: ClinicalTrials.gov · NCT05758246 · last updated 2026-09-01